Andrea Taborelli, Business Development and Licensing Manager – IBSA

IBSA is a regular presence at the Cphi events. After Tokyo, you will be present again this year at Cphi Worldwide 2023 in Barcelona, with what goals?
In April we were at Cphi Japan: it was the first time we were back in Tokyo after the Covid pandemic and it was really exciting to be part of such a buzzing and lively event. It was fantastic also to see the level of interest and engagement we received from attendees who stopped by our stand to see what IBSA’s world could offer them in term of pharmaceutical solutions. So we could not miss this new appointment of Cphi Worldwide, in Barcelona. Last year’s edition, in Frankfurt, registered almost 46,000 visitors from 171 countries: such an opportunity only happens once a year and we certainly don’t want to miss this unique chance to meet international industry professionals, expand our network, give visibility to our products, test the interest in our solutions for the pharmaceutical markets and obviously keep up to date with the latest industry trends.

Let’s give some sneak peeks: what are the products you are most focusing on and prioritising in Barcelona? What are their distinctive features thanks to which you think you will be able to capture the attention of the public at the fair?
IBSA is one of the world leaders in the production of hyaluronic acid by bio-fermentation. Today, thanks to cutting-edge research and patented technology (NAHYCO®) IBSA is able to obtain unique hybrid complexes of high and low molecular weight hyaluronic acid.
Thanks to this patented production process IBSA has developed the innovative SINOVIAL® HL pre-filled syringes for intra-articular injection, indicated for pain or reduced mobility due to degenerative diseases (arthrosis), post-traumatic diseases and tendinopathy associated with joint disabilities. Its efficacy is already evident starting from the first injection and it lasts up to 6 months, suggesting a long-lasting carry-over effect of the treatment. More recently IBSA also launched Sinogel®. It is a prefilled syringe containing a Hybrid cooperative complex of highly purified sodium hyaluronate with high molecular weight and sodium chondroitin containing the highest quantity of glycosaminoglycans (GAGs) in the market.
Among the hyaluronic acid products we will be presenting, there is also Ialuril® Prefill which is indicated to re-establish the glycosaminoglycan layers (GAGs) of the urothelial vesical tissue in cases their loss can cause frequent and recurring problems (such as, for example, cystitis of different etiology). The product is also indicated when the loss of the glycosaminoglycan layer is associated with forms of chronic inflammation.